Praxis Precision Medicines (PRAX) Gets a Buy From Piper Sandler
Nvidia, Micron Leading Chip Stocks Higher Tuesday
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday.Shares of NVIDIA Corporation (NASDAQ:NVDA) rose during Tuesday's session.Keybanc analyst John Vinh maintained
Praxis Precision Med Is Maintained at Overweight by Piper Sandler
Praxis Precision Med Is Maintained at Overweight by Piper Sandler
Piper Sandler Initiates a Buy Rating on Praxis Precision Medicines (PRAX)
Value Of Praxis Precision Medicines' Lead Program In Essential Tremor Alone Is Underappreciated: Analyst
Needham initiated coverage on Praxis Precision Medicines Inc (NASDAQ:PRAX), a clinical-stage biopharmaceutical company, engaged in the development of therapies for central nervous system disorders.The
Needham Initiates Praxis Precision Medicines(PRAX.US) With Buy Rating, Announces Target Price $145
Needham analyst Ami Fadia initiates coverage on $Praxis Precision Medicines(PRAX.US)$ with a buy rating, and sets the target price at $145.According to TipRanks data, the analyst has a success rate of
Praxis Precision Med Initiated at Buy by Needham
Praxis Precision Med Initiated at Buy by Needham
Express News | Praxis Precision Medicines Inc : Needham Initiates Coverage With Buy Rating; Price Target $145
Express News | Needham Initiates Coverage On Praxis Precision Medicine With Buy Rating, Announces Price Target of $145
Baird Sees Jazz Study Failure as Positive for Rival Praxis
Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersTempest Therapeutics (NASDAQ:TPST) shares rose 32.8% to $3.79 during Thursday's pre-market session. The company's market cap stands at $84.0 million. Neurogene (NASDAQ:NGNE) shares rose 31.92%
Express News | Praxis Precision Medicines Shares Are Trading Higher After Guggenheim Initiated Coverage With a Buy Rating and a $155 Price Target
Express News | Praxis Precision Medicines Inc : Guggenheim Initiates Coverage With Buy Rating; Target Price $155
Praxis Precision Med Initiated at Buy by Guggenheim
Praxis Precision Med Initiated at Buy by Guggenheim
Guggenheim Initiates Praxis Precision Medicines(PRAX.US) With Buy Rating, Announces Target Price $155
Guggenheim analyst Yatin Suneja initiates coverage on $Praxis Precision Medicines(PRAX.US)$ with a buy rating, and sets the target price at $155.According to TipRanks data, the analyst has a success r
Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $270
Piper Sandler analyst Yasmeen Rahimi maintains $Praxis Precision Medicines(PRAX.US)$ with a buy rating, and maintains the target price at $270.According to TipRanks data, the analyst has a success rat
Truist Financial Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating
Truist Financial analyst Joon Lee maintains $Praxis Precision Medicines(PRAX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.3% and a total average return of 23
Express News | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan